ОСОБЕННОСТИ ИММУННОГО РЕАГИРОВАНИЯ НА ВИРУС SARS-COV-2.

ПРЕПРИНТ

Эта статья является препринтом и не была отрецензирована.
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.

Гришаева А. А.,

Турапова А. Н.,

Понежева Ж. Б.,

Алешина Н. И.,

Малеев В. В.

2020-10-29

https://doi.org/10.21055/preprints-3111900

Клинические проявления новой коронавирусной инфекции разнообразны, от бессимптомного течения до развития острого респираторного дистресс-синдрома и мультиорганной дисфункции. В настоящее время доказано, что тяжесть состояния коррелирует с повышением уровня воспалительных цитокинов, таких как IL6, IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A и TNFa. Данное явление получило название «цитокинового шторма». В данном обзоре рассмотрены современные представления об особенностях иммунного ответа на SARS-COV2.

Ссылка для цитирования:

Гришаева А. А., Турапова А. Н., Понежева Ж. Б., Алешина Н. И., Малеев В. В. 2020. ОСОБЕННОСТИ ИММУННОГО РЕАГИРОВАНИЯ НА ВИРУС SARS-COV-2. COVID19-PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111900

Список литературы

1. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. 10.1016/S0140-67362030183-5

2. Ruan Q, Yang K, Wang W et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. (2020) 46:846–8. 10.1007/s00134-020-06028-z

3. Chen G, Wu D, Guo W et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. (2020) 130:2620–9. 10.1101/2020.02.16.20023903

4. Gao Y, Li T, Han M et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. (2020) 92:791–6. 10.1002/jmv.25770

5. Chen L, Liu H, Liu W et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. (2020) 43:203–8. 10.3760/cma.j.issn.1001-0939.2020.0005

6. Sun D, Li H, Lu X et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. World J Pediatr. (2020) 19:1–9. 10.1007/s12519-020-00354-4

7. Braciale T, Hahn Y. Immunity to viruses. Immunol Rev. (2013) 255:10.1111/imr.12109.10.1111/imr.12109

8. Yujun Tang, Jiajia Liu, Dingyi Zhang et al. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Front Immunol. 2020; 11: 1708. 10.3389/fimmu.2020.01708

9. Thompson M, Kaminski J, Kurt-Jones E et al. Pattern recognition receptors and the innate immune response to viral infection. Viruses. (2011) 3:920–40. 10.3390/v3060920

10. Dina Ragab, Haitham Salah Eldin, Mohamed Taeimah et al. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020; 11: 1446. 10.3389/fimmu.2020.01446

11. Zhong-yong C, Wei-bin Y, Qiang W et al. Clinical significance of serum hs-CRP, IL-6, and PCT in diagnosis and prognosis of patients with COVID-19. Drugs Clin. (2020) 35:417–20. 10.7501/j.issn.1674-5515.2020.03.005

12. Guohua L, Ling L, Min H et al. Value of various inflammatory markers combined with lymphocyte subsets on clinical diagnosis of different clinical types of COVID-19. J Chong Med Univ. (2020). 10.13406/j.cnki.cyxb.002465.

13. Tanaka T., Narazaki M., Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959–970.

14. Hunter C.A., Jones S.A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 2015;16(5):448–457.

15. Xinjuan Sun, Tianyuan Wang, Dayong Cai et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020 Jun; 53: 38–42. 10.1016/j.cytogfr.2020.04.002

16. Hay K.A., Hanafi L.A., Li D. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295–2306.

17. Xiong Y, Liu Y, Cao L et al . Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. (2020) 9:761–70. 10.1080/22221751.2020.1747363

18. Herbinger KH, Hanus I, Beissner M, et al. Lymphocytosis and Lymphopenia Induced by Imported Infectious Diseases: A Controlled Cross-Sectional Study of 17,229 Diseased German Travelers Returning from the Tropics and Subtropics. Am J Trop Med Hyg. 2016;94(6):1385-1391.

19. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan. China. Clin Infect Dis. 2020.

20. Xu Z., Shi L., Wang Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020

21. Chen X, Ling J, Mo P et al. Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients. medRxiv [preprint]. (2020). 10.1101/2020.03.03.20030437

22. Zheng M, Gao Y, Wang G et al. . Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. (2020) 17:533–5. 10.1038/s41423-020-0402-2

23. Chen Y, Feng Z, Diao B, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. medRxiv. (2020). 10.1101/2020.03.27.20045427

24. Li J, Guo M, Tian X et al. Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis. bioRxiv. (2020). 10.1101/2020.03.31.019216

ПРЕПРИНТ

ИНФОРМАЦИЯ О ПРЕПРИНТЕ